HopeStage
Back to all studies
CompletedNCT00488566

GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers

Medication studyAges 18–65United KingdomBipolarity
The study in practice

Understand this study

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Harrow and 1 more locationSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 31, 2007
Recruitment status
Completed
Enrollment listed in the registry
50
Sponsor
Biogen
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 65 Years
Official registry ID
NCT00488566
Official title
Show the full official title

Double Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of GSK Drug and the Effect of Single Doses of GSK Drug or Lamotrigine on Resting Motor Threshold in Healthy Volunteers

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Harrow · London

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Biogen.

Did this study involve medication?

Yes. The study involved medication, including GSK drug.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies